Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Donepezil tablets (mild to moderate Alzheimer disease) - selected U.S. labeling
Product / population
Adults with mild to moderate Alzheimer disease; oral 5 mg and 10 mg tablets. This summary excludes the 23 mg regimen and transdermal formulations.
Renal method
Indexed clearance in the label pharmacokinetic study; not an automatic renal dose-selection equation.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Official
Donepezil tablets (mild to moderate Alzheimer disease) - selected U.S. labeling
U.S. product labeling / DailyMed · Adults with mild to moderate Alzheimer disease; oral 5 mg and 10 mg tablets. This summary excludes the 23 mg regimen and transdermal formulations.
Renal method: Indexed clearance in the label pharmacokinetic study; not an automatic renal dose-selection equation. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Start 5 mg orally each evening. A 10 mg daily dose may be used only after 4-6 weeks at 5 mg; 10 mg/day is the labeled maximum for this disease-severity scope.
A study of 11 subjects with renal clearance below 18 mL/min/1.73 m2 found no difference in donepezil clearance versus matched controls. No separate numeric renal or dialysis regimen is given in the selected label.
Monitor for bradycardia/heart block, syncope, gastrointestinal adverse effects and weight loss. Do not transfer this titration to another dosage form or disease-severity regimen.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.